<DOC>
	<DOCNO>NCT00447382</DOCNO>
	<brief_summary>The trial conduct Germany , The Republic Macedonia , Russian Federation , Serbia South Africa . The aim trial make safety comparison insulin detemir produce new production method ( NN729 ) insulin detemir make previous production method ( NN304 ) . Subjects treat NN729 NN304 period 52 week total daily dose frequency administration pre-trial basal insulin . During trial dos individualise base subject 's plasma glucose measurement .</brief_summary>
	<brief_title>Safety Insulin Detemir Produced New Process Measured Antibody Formation Subjects With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Type 1 diabetes least 12 month Basalbolus treatment least 3 month Body Mass Index ( BMI ) less equal 35.0 kg/m^2 HbA1c ( glycosylated haemoglobin ) less equal 12.0 % Known suspect allergy trial product relate product Pregnancy , breastfeed intention become pregnant use adequate contraceptive measure Receipt trial drug within 1 month prior trial Mental incapacity , unwillingness language barrier preclude adequate understanding cooperation Conditions may interfere trial participation judge Investigator : proliferative retinopathy maculopathy require acute treatment within last six month , recurrent major hypoglycaemia , impaired hepatic renal function , cardiac problem , uncontrolled hypertension ( treat untreated )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>